Skip to main content
SpringerLink
Log in

Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet 1999 Aug 14;354(9178):602]. Lancet. 1998;352(9131):837–853.

  2. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi:https://doi.org/10.1056/NEJMoa0802987

  3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007 Jul 5;357(1):100.]. N Engl J Med. 2007;356(24):2457–71. https://doi.org/10.1056/NEJMoa072761.

  4. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials [published correction appears in BMJ. 2022 Jan 18;376:o109]. BMJ. 2021;372:m4573. https://doi.org/10.1136/bmj.m4573(Published 2021 Jan 13).

  5. Ala M. SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD. Endocrinology. 2021;162(12):bqab157. https://doi.org/10.1210/endocr/bqab157.

  6. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–62. https://doi.org/10.1016/S2213-8587(21)00203-5.

    Article  CAS  PubMed  Google Scholar 

  7. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57. https://doi.org/10.2337/dc23-S009.

  8. Sağlık Uygulama Tebliği. Part 4.2.38, diabetes medications use policy. Sosyal Güvenlik kurumu, SGK. https://www.sgk.gov.tr/Duyuru/Detay/20230316-Degisiklik-Tebligi-Islenmis-Guncel-2013-SUT-2023-03-20-02-54-56. Retrieved 21 Apr 2023.

  9. Choi JG, Winn AN, Skandari MR, et al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med. 2022;175(10):1392–400. https://doi.org/10.7326/M21-2941.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Reifsnider OS, Kansal AR, Gandhi PK, et al. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Res Care. 2021;9(1):e001313. https://doi.org/10.1136/bmjdrc-2020-001313.

    Article  PubMed  PubMed Central  Google Scholar 

  11. World Economic Outlook Database, April 2023. imf.org. International Monetary Fund. Retrieved 10 May 2023.

Download references

Funding

No funding was received

Author information

Authors and Affiliations

  1. Division of General Internal Medicine, Department of Internal Medicine, Faculty of Medicine, Başkent University, Ankara, Turkey

    Alper Tuna Güven

Authors
  1. Alper Tuna Güven
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alper Tuna Güven.

Ethics declarations

Conflict of interest

The author declares no conflict of interest

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Güven, A.T. Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey. PharmacoEconomics 41, 843–844 (2023). https://doi.org/10.1007/s40273-023-01282-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-023-01282-7

Search

Navigation